81 |
Effect of simvastatin pretreatment on immunologic memory and survival in response to secondary Staphylococcus aureus infectionSmelser, Lisa K. 04 May 2013 (has links)
Access to abstract restricted until May 2016. / Access to thesis restricted until May 2016 / Department of Biology
|
82 |
Lipidų apykaitos sutrikimo gydymui ir profilaktikai vartojamų vaistų ir maisto papildų įvertinimas Lietuvos vaistinėse / Evaluation of Medicine and Food Supplements used to Treat and Prevent the Disorder of Lipid Metabolism in the Lithuanian PharmaciesMacijauskaitė, Simona 18 June 2013 (has links)
Darbo tikslas: nustatyti, vaistinėse besilankančių pacientų, lipidų apykaitos sutrikimo profilaktikai ir gydymui rekomenduojamų vaistinių preparatų ir maisto papildų suvartojimo tendencijas. Uždaviniai: 1) išanalizuoti statinų grupės preparatų suvartojimą Lietuvoje 2005-2012 metais, naudojant tarptautinę, PSO patvirtintą, vaistų suvartojimo ATC/DDD metodiką ir gautus rezultatus palyginti su kitomis ES šalimis, 2) įvertinti, vaistinėse besilankančių pacientų, lipidogramos rodiklius ir jų dinamiką, vartojant antilipideminius vaistus ir maisto papildus, 3) įvertinti lipidų apykaitos sutrikimo profilaktikai ir gydymui rekomenduojamų vaistų ir maisto papildų atitikimą tarptautinėms rekomendacijoms (NCEP ATP III). Metodika: vaistų, kurie priklauso C10AA (HMG KoA reduktazės inhibitorių) ir C10BX (HMG KoA reduktazės inhibitorių, kitų derinių) pogrupiams, suvartojimas buvo analizuojamas ATC/DDD metodika, išreiškiant duomenis DDD/1000 gyventojų per dieną (DDD/1000 gyv/d). Vaistinėje besilankančių pacientų lipidogramos rodikliai ir vartojami vaistai/maisto papildai buvo vertinami atliekant anketinę apklausą. Surinktų duomenų statistinė analizė atlikta naudojant SPSS programinį paketą, 17,0 versiją. Rezultatai: statinų suvartojimas Lietuvoje padidėjo nuo 3,873 DDD/1000 gyv/d 2005 m. iki 12,787 DDD/1000 gyv/d 2012 m., o išlaidos išaugo nuo 6,19 mln Lt 2005 m. iki 9,12 mln Lt 2012 m. Anketinėje apklausoje dalyvavo 358 pacientai, kurie vaistinėje įsigijo vaistus ir/ar maisto papildus lipidų... [toliau žr. visą tekstą] / Objective of the work: to determine the usage tendencies of the medicinal products and food supplements recommended for prevention and treatment of the disorder of lipid metabolism to the patients coming to the pharmacies. Tasks: 1) to analyze the usage of the products of statin group in Lithuania in 2005-2012 using the international, WHO approved methodology of the medicine usage ATC/DDD, and to compare the results with other EU States, 2) to assess the indexes of lipidogram and their dynamics of the patients coming to the pharmacies, who use antilipidemic medicine and food supplements, 3) to assess the conformity of the medicinal products and food supplements recommended for prevention and treatment of the disorder of lipid metabolism to the international guidelines (NCEP ATP III). Methodology: the usage of the medicine that belongs to the sub-groups of C10AA (HMG CoA reductase inhibitors) and C10BX (Other combinations) was analyzed by the ATC/DDD methodology expressing the data as DDD/1000 inhabitants per day (DDD/1000 inhabitants/d). The indexes of lipidogram and the medicine/food supplements used by the patients coming to the pharmacies were assessed using the survey by questionnaires. The statistical analysis of the collected data was done using the SPSS program package, version 17.0. Results: the usage of statins in Lithuania increased from 3,873 DDD/1000 inhabitants/d in 2005 until 12,787 DDD/1000 inhabitants/d in 2012, while the expenses for statins increased from 6... [to full text]
|
83 |
Regulation of lipoprotein transport in the metabolic syndrome : impact of statin therapyOoi, Esther M. M. January 2007 (has links)
[Truncated abstract] The metabolic syndrome is characterized by cardiovascular risk factors including dyslipidemia, insulin resistance, visceral obesity, hypertension and diabetes. The dyslipidemia of the metabolic syndrome includes elevated plasma triglyceride and apolipoprotein (apo) B levels, accumulation of small, dense low-density lipoprotein (LDL) particles and low high-density lipoprotein (HDL) cholesterol concentration. However, the precise mechanisms for this dyslipoproteinemia, specifically low plasma HDL cholesterol, are not well understood. This thesis therefore, focuses on HDL, its structure, function and metabolism. However, lipoprotein metabolism is a complex interconnected system, which includes forward and reverse cholesterol transport pathways. Hence, this thesis also examines and discusses the metabolism of apoB-containing lipoproteins. This thesis tests the general hypothesis that apolipoprotein kinetics are altered in the metabolic syndrome, and that lipid regulating therapies can improve these kinetic abnormalities. The aims were first, to compare and establish the clinical, metabolic and kinetic differences between metabolic syndrome and lean subjects; and second, to determine the regulatory effects of statin therapy, specifically, rosuvastatin on lipoprotein transport in the metabolic syndrome. Five observation statements were derived from the general hypothesis and examined in the studies described below. The findings are presented separately as a series of original publications. Study 1 Twelve men with the metabolic syndrome and ten lean men were studied in a case-control setting. ... These findings explain the HDL raising effects of rosuvastatin in the metabolic syndrome. Collectively, these studies suggest that the dyslipidemia of the metabolic syndrome results from increased production rates of VLDL and LDL particles, reduced fractional catabolic rates of these lipoproteins, together with accelerated catabolism of HDL particles. Treatment with rosuvastatin increases the catabolic rates of all apoB-containing lipoproteins and at a higher dose, decreases LDL apoB production. These effects are consistent with inhibition of cholesterol synthesis leading to an upregulation of LDL receptors. Rosuvastatin decreases the fractional catabolism of HDL particles. The effects of rosuvastatin on HDL kinetics may be related to a reduction in triglyceride concentration and cholesterol ester transfer protein activity. These findings are consistent with the general hypothesis that apolipoprotein kinetics are altered in the metabolic syndrome, and that statin therapy improves these kinetic abnormalities.
|
84 |
Impact of N-2-mercaptopropionylglycine (MPG) and simvastatin on exercise-induced cardiac adaptationsNelson, Matthew Jay. January 1900 (has links)
Thesis (Ph. D.)--University of Texas at Austin, 2008. / Vita. Includes bibliographical references.
|
85 |
Coenzyme Q10 for statin-induced myopathy : a systematic reviewPietersen, Lauren 12 1900 (has links)
Thesis (MNutrition (ITE))--Stellenbosch University, 2012. / ENGLISH ABSTRACT: Background
Statins are drugs of known efficacy in the treatment of hypercholesterolaemia. However, statin-induced myopathy, an adverse effect of statins in up to 15% of its users, has warranted a reduction in the prescription dose or discontinuation of the drug. The exact mechanism of statin-induced myopathy is unknown, but the potential of Coenzyme Q10 (CoQ10) as treatment has been recognized due to decreased human plasma CoQ10 levels found after statin use and the concomitant role of CoQ10 in muscle function.
Objectives
This systematic review assessed the effect of CoQ10 supplementation on: the severity of statin-induced myopathic symptoms, levels of plasma creatine kinase, intramuscular and plasma CoQ10, as well as whether any adverse effects of CoQ10 supplementation such as abdominal pain, nausea and vomiting or headaches were experienced.
Search methods
Two searches for studies were conducted in The Cochrane Central Register of Controlled Trials (inception to March 2011 and inception to November 2011), MEDLINE (inception to March 2011 and inception to November 2011), Web of Science (inception to March 2011 and inception to November 2011), Science Direct (inception to March 2011 and inception to February 2012), Wiley Online Library (inception to March 2011 and inception to February 2012), Springerlink (inception to April 2011 and inception to February 2012), EBSCOhost [Academic Search Premier and CAB abstracts (inception to March 2011 and inception to February 2012), CINAHL (inception to March 2011 and inception to November 2011)], Scopus (inception to March 2011 and inception to November 2011) and Google Scholar (inception to March 2011 and inception to February 2012). Reference lists of articles were hand searched for relevant clinical trials. Only trials with a full text were included in the review. Selection criteria
Randomised controlled trials (RCTs) were included with adult participants (mean of 18-64.99 years) of all race/ethnic groups and gender on statin therapy with reported myopathic symptoms from an unknown cause. The intervention was in the form of a pure oral supplement of CoQ10 irrespective of dose, duration and frequency, and the control in the form of a placebo, a similar antioxidant, or no intervention. Outcomes included the severity of myopathic symptoms, levels of plasma creatine kinase (U/L), intramuscular CoQ10 (μmol/kg) and plasma CoQ10 (μmol/L), as well as adverse effects of CoQ10.
Data collection and analysis
The principle investigator and one independent reviewer selected the studies, extracted data and assessed for risk of bias using the Cochrane Collaboration‘s tool for assessing risk of bias. Authors of relevant clinical trials were contacted for additional information.
Results
Two RCTs were included in the review, totaling 76 participants. A meta-analysis could not be performed, thus the review is narrative. There were an insufficient number of RCTs to confirm whether routine supplementation of CoQ10 improves statin-induced myopathic symptoms.
Conclusions
More and larger RCTs are required to determine the efficacy of CoQ10 supplementation in statin-induced myopathy. Consensus needs to be reached regarding the definition and measurement instrument/s of myopathy so that results of future studies can easily be compared and synthesized. / AFRIKAANSE OPSOMMING: Agtergrond
Statiene is medikasie bekend vir die effektiewe behandeling van hipercholesterolemie. Statien-geïnduseerde miopatie is egter 'n newe-effek wat voorkom in tot 15% van gebruikers, wat 'n vermindering in die voorgeskrewe dosis of staking van die medikasie tot gevolg het. Die presiese meganisme van statien-geïnduseerde miopatie is onbekend, maar die potensiaal van Koënsiem Q10 (CoQ10) is geïdentifiseer as 'n moontlike behandeling aangesien menslike plasma CoQ10 vlakke verlaag na die gebruik van statiene en as gevolg van die rol van CoQ10 in spierfunksie.
Doelwitte
Hierdie sistematiese literatuuroorsig het die effek van CoQ10 supplementasie bepaal op: die graad van statien-geïnduseerde miopatiese simptome, plasma kreatien kinase vlakke, intra-muskulêre en plasma CoQ10 vlakke, asook die teenwoordigheid van enige newe-effekte van CoQ10 supplementasie soos abdominale pyn, naarheid en braking of hoofpyne.
Soektogstrategie
Twee soektogte vir studies is uitgevoer in The Cochrane Central Register of Controlled Trials (ontstaan tot Maart 2011 en ontstaan tot November 2011), MEDLINE (ontstaan tot Maart 2011 en ontstaan tot November 2011), Web of Science (ontstaan tot Maart 2011 en ontstaan tot November 2011), Science Direct (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), Wiley Online Library (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), Springerlink (ontstaan tot April 2011 en ontstaan tot Februarie 2012), EBSCOhost [Academic Search Premier en CAB abstracts (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012), CINAHL (ontstaan tot Maart 2011 en ontstaan tot November 2011)], Scopus (ontstaan tot Maart 2011 en ontstaan tot November 2011) en Google Scholar (ontstaan tot Maart 2011 en ontstaan tot Februarie 2012). Verwysingslyste van artikels is ook met die hand nagegaan vir relevante kliniese proewe. Slegs kliniese proewe waarvan die volteks beskikbaar was, is ingesluit in die oorsig. Seleksiekriteria
Ewekansige gekontroleerde proewe (EGP) is ingesluit met volwasse deelnemers (gemiddeld 18-64.99 jaar) van alle rasse/etniese groepe en geslag op statien-terapie met gerapporteerde miopatie simptome van onbekende oorsaak. Die intervensie was 'n suiwer orale supplement van CoQ10 ongeag die dosis, duurte en frekwensie, en die kontrole 'n plasebo, soortgelyke antioksidant, of geen intervensie. Uitkomste het ingesluit: die graad van miopatie simptome, vlakke van plasma kreatien kinase (U/L), intra-muskulêre CoQ10 (μmol/kg) en plasma CoQ10 (μmol/L), sowel as newe-effekte van CoQ10.
Dataversameling en -analise
Die hoof ondersoeker en een onafhanklike hersiener het die seleksie van studies en data-ekstraksie onderneem en die risiko vir sydigheid geassesseer deur gebruik te maak van die Cochrane Collaboration’s tool for assessing risk of bias. Outeurs van relevante kliniese proewe is geraadpleeg vir addisionele inligting
Resultate
Twee EGP is ingesluit in die oorsig met 'n totaal van 76 deelnemers. 'n Meta-analise kon nie uitgevoer word nie, dus is die oorsig beskrywend. Daar was te min EGP om te bewys dat roetine supplementasie van CoQ10 statien-geïnduseerde miopatiese simptome verbeter.
Gevolgtrekkings
Meer en groter EGP is nodig om die effektiwiteit van CoQ10 supplementasie in statien-geïnduseerde miopatie te bepaal. Konsensus moet bereik word ten opsigte van die definisie en metingsinstrument/e van miopatie sodat die resultate van toekomstige studies makliker vergelyk en verwerk kan word.
|
86 |
Effect of statin treatment on preterm labourBoyle, Ashley Kathryn January 2017 (has links)
Preterm labour (PTL) is defined as labour before 37 completed weeks of gestation. Despite advances in medical research, PTL remains a major clinical problem. Preterm birth (PTB) rates range from approximately 5-18% worldwide. Importantly, PTB is the leading cause of childhood morbidity and mortality. PTL is difficult to predict and the aetiology is poorly understood but infection and inflammation are believed to be major factors. It has been suggested that the presence of intrauterine infection or inflammation may initiate the pathological, preterm activation of the inflammatory cascade associated with term labour. Therefore, PTL therapeutics should aim to inhibit these inflammatory pathways. Statins, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are potent inhibitors of cholesterol biosynthesis, which act on the mevalonate pathway. In addition to their lipid-lowering effects, statins also have anti-inflammatory and anti-contraction properties. The hypothesis of this thesis was that statins will prevent PTB by reducing inflammation. The aims of this thesis were firstly to investigate the effect of the statins, simvastatin and pravastatin, on inflammation and contractility in a pregnant human myometrial cell line. Secondly, to determine whether simvastatin and/or pravastatin can prevent PTB or improve neonatal outcome in a lipopolysaccharide (LPS)-induced mouse model of PTB. Myometrial cells were either co-treated with LPS and simvastatin/pravastatin, pretreated with simvastatin/pravastatin or treated with simvastatin/pravastatin post-LPS stimulation. The effect of statin treatment on the mRNA expression and the release of inflammatory mediators was then investigated. Simvastatin treatment reduced LPS-induced inflammation by both lowering the expression of pro-inflammatory mediators and increasing the expression of anti-inflammatory mediators. Pravastatin treatment did not alter the expression of inflammatory mediators following LPS stimulation. The effect of simvastatin on the contraction of myometrial cells was investigated by embedding the cells in rat tail collagen to form gels. As these are smooth muscle cells, basal contraction was observed causing the gel size to reduce. When LPS was introduced, this caused the gels to contract further than the vehicle treated gels. Simvastatin attenuated the contraction of the myometrial cells, both alone and in the presence of LPS. These effects were reversed by the addition of mevalonate pathway metabolites, mevalonate and geranylgeranyl pyrophosphate (GG-PP) but not by farnesyl pyrophosphate (F-PP). Simvastatin also lowered levels of phosphorylated myosin light chain (pMLC) in the myometrial cells, which is essential for smooth muscle contraction. Again, this effect was abolished by mevalonate and GG-PP but not F-PP. It is hypothesised that simvastatin attenuated myometrial cell contraction by inhibiting Rho isoprenylation by GG-PP, preventing Rho-associated kinase (ROCK) activation, which then prevented the phosphorylation of MLC. A mouse model of intrauterine LPS-induced PTB was utilised to investigate the effect of statin treatment on PTB and fetal survival. Mice received an intraperitoneal injection of pravastatin (10μg) or simvastatin (20μg or 40μg) on gestational day (D)16. This was followed by ultrasound-guided intrauterine injection of LPS (1μg) on D17 and another pravastatin/simvastatin treatment two hours later. When mice were treated with LPS, 77.8% of mice delivered preterm. When mice received LPS and 20μg simvastatin, 50% delivered preterm. However, when mice were treated with LPS and 40μg simvastatin, 40% delivered preterm, more pups were born alive and uterine pro-inflammatory mRNA expression was downregulated. Conversely, pravastatin did not prevent PTB or improve the percentage of live born pups. In summary, simvastatin treatment exerted anti-inflammatory and anti-contraction effects on human myometrial cells in vitro. The anti-contractile properties were likely due to the inhibition of the Rho/ROCK pathway. Furthermore, in our LPS-induced mouse model of PTB, fewer mice delivered preterm with simvastatin treatment, simvastatin attenuated LPS-induced pup mortality and reduced uterine inflammatory gene expression. These results suggest that statin therapy may be a novel treatment for PTL.
|
87 |
Investigação da atividade toxicológica de análogos de estatinas em modelos experimentais in vitro / Investigation of statin analogues toxicological activity using in vitro experimental modelsCarlos Fernando Araujo Lima de Oliveira 12 March 2014 (has links)
Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / As estatinas são fármacos inibidores competitivos da enzima hidroxi-3-metil-glutaril Coenzima A (HMGCoA) redutase, amplamente utilizados para o controle da hipercolesterolemia total e, em especial, para a redução dos níveis séricos de LDLc (Low Density Lipoprotein cholesterol). Além do efeito primário, esses fármacos apresentam vários efeitos secundários, chamados de efeitos pleiotrópicos, envolvendo atividade anti-inflamatória, antitumoral e antiparasitária. Para o desenvolvimento de inovações na área de química medicinal é imprescindível avaliar o risco de efeitos adversos para saúde ou, em outras palavras, a segurança terapêutica do novo produto nas condições propostas de uso. Nesse sentido, o objetivo desse trabalho foi investigar a genotoxicidade de quatro análogos inibidores da biossíntese de lipídios, da classe das estatinas, em modelos experimentais in vitro, testados previamente contra o clone W2 de Plasmodium falciparum a fim de se obter o IC50 dessas moléculas frente ao patógeno. Foram desenvolvidas quatro novas moléculas (PCSR02.001, PCSR09.001, PCSR08.002 e PCSR10.002). Para a avaliação da toxicidade, foram realizados o teste de mutagenicidade bacteriana (teste de Ames), o ensaio de viabilidade celular utilizando o reagente WST-1 e o ensaio de indução de micronúcleos, ambos utilizando uma linhagem ovariana (CHO-K1) e uma linhagem hepática (HepG2). Levando em conta o fato de nenhuma das amostras ter induzido efeitos mutagênicos nas linhagens de S. enterica sorovar Typhimurium, e PCSR10.002 ter apresentado citotoxicidade sugere-se então que este composto seja o mais tóxico. Comparativamente, PCSR10.002 foi mais genotóxico e citotóxico para a linhagem CHO-K1 do que para a linhagem HepG2. PCSR02.001 apresentou elevado potencial genotóxico para células ovarianas, mas não foi capaz de induzir a formação de micronúcleos em células hepáticas, apresentando, portanto um perfil similar ao observado em PCSR10.002. Assim como a atorvastatina, PCSR09.001 apresentou elevado potencial pró-apoptótico para a linhagem de hepatócitos. Já PCSR08.002, apresentou aumento na apoptose de CHO-K1. A indução de apoptose não é necessariamente um evento negativo, já que é pouco lesiva e responsável pela eliminação de células danificadas. Porém, as respostas de apoptose induzidas por esse composto foram muito inferiores àquelas induzidas pela atorvastatina (cerca de 4 vezes menor que a atorvastatina). PCSR08.002 foi aquele se mostrou menos tóxico e essa amostra foi a que teve menor risco relativo, em uma análise global das respostas de citotoxicidade e não demonstrou ter potencial genotóxico para as linhagens utilizadas nesse estudo. Conclui-se, portanto, que a análise da atividade toxicológica utilizando modelos experimentais in vitro dessas estatinas constitui um importante passo para o estabelecimento de novos candidatos à fármacos com maior segurança. / Statin drugs are competitive inhibitors of the enzyme 3-hydroxy-methyl-glutaryl coenzyme A (HMGCoA) reductase, widely used for the control of hypercholesterolemia and overall, in particular for the reduction of serum LDLc (Low Density Lipoprotein cholesterol). In addition to the primary effect, these drugs have many secondary effects, called pleiotropic effects, involving anti-inflammatory, antitumor, and antiparasitic activities. For the development of innovations in the field of medicinal chemistry is essential to evaluate the risk of adverse health effects, or in other words, the therapeutic safety of the new product under the proposed conditions of use. Accordingly, the aim of this study was to investigate the genotoxicity of four analogues of lipid biosynthesis inhibitors, from the class of statins in experimental models in vitro, previously tested against the W2 clone of Plasmodium falciparum to obtain the IC50 of these molecules against the pathogen. Four new molecules (PCSR02.001, PCSR09.001, PCSR08.002 and PCSR10.002) were developed. For the assessment of toxicity, bacterial mutagenicity test (Ames test) were performed, the cell viability assay using WST-1 reagent and micronuclei induction assay, both using an ovarian lineage (CHO-K1) and an hepatic lineage (HepG2). Taking into account the fact that none of the samples have induced mutagenic effects in strains of S. enterica serovar Typhimurium , and PCSR10.002 have shown cytotoxicity then we suggest that this compound is the most toxic. Comparatively, PCSR10.002 was more cytotoxic and genotoxic for the CHO-K1 cell line, than for HepG2 line. PCSR02.001 showed high genotoxic potential for ovarian cells, but was not able to induce the formation of micronuclei in liver cells, thus showing a similar profile to that observed in PCSR10.002. Just like atorvastatin, PCSR09.001 showed high pro-apoptotic potential for hepatocyte lineage. Have PCSR08.002, showed an increase in apoptosis of CHO-K1. The induction of apoptosis is not necessarily an adverse event, since little is harmful and responsible for the elimination of damaged cells. However, the apoptotic responses induced by this compound were much lower than those induced by atorvastatin (about 4 times less than atorvastatin). PCSR08.002 was that was less toxic and this sample had a lower relative risk in a global analysis of the responses and cytotoxicity demonstrated no genotoxic potential for strains used in this study. Therefore it is concluded that the analysis of toxicological activity using in vitro experimental models of these statins is an important step towards the establishment of more safely new candidate-drugs.
|
88 |
Investigação da atividade toxicológica de análogos de estatinas em modelos experimentais in vitro / Investigation of statin analogues toxicological activity using in vitro experimental modelsCarlos Fernando Araujo Lima de Oliveira 12 March 2014 (has links)
Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / As estatinas são fármacos inibidores competitivos da enzima hidroxi-3-metil-glutaril Coenzima A (HMGCoA) redutase, amplamente utilizados para o controle da hipercolesterolemia total e, em especial, para a redução dos níveis séricos de LDLc (Low Density Lipoprotein cholesterol). Além do efeito primário, esses fármacos apresentam vários efeitos secundários, chamados de efeitos pleiotrópicos, envolvendo atividade anti-inflamatória, antitumoral e antiparasitária. Para o desenvolvimento de inovações na área de química medicinal é imprescindível avaliar o risco de efeitos adversos para saúde ou, em outras palavras, a segurança terapêutica do novo produto nas condições propostas de uso. Nesse sentido, o objetivo desse trabalho foi investigar a genotoxicidade de quatro análogos inibidores da biossíntese de lipídios, da classe das estatinas, em modelos experimentais in vitro, testados previamente contra o clone W2 de Plasmodium falciparum a fim de se obter o IC50 dessas moléculas frente ao patógeno. Foram desenvolvidas quatro novas moléculas (PCSR02.001, PCSR09.001, PCSR08.002 e PCSR10.002). Para a avaliação da toxicidade, foram realizados o teste de mutagenicidade bacteriana (teste de Ames), o ensaio de viabilidade celular utilizando o reagente WST-1 e o ensaio de indução de micronúcleos, ambos utilizando uma linhagem ovariana (CHO-K1) e uma linhagem hepática (HepG2). Levando em conta o fato de nenhuma das amostras ter induzido efeitos mutagênicos nas linhagens de S. enterica sorovar Typhimurium, e PCSR10.002 ter apresentado citotoxicidade sugere-se então que este composto seja o mais tóxico. Comparativamente, PCSR10.002 foi mais genotóxico e citotóxico para a linhagem CHO-K1 do que para a linhagem HepG2. PCSR02.001 apresentou elevado potencial genotóxico para células ovarianas, mas não foi capaz de induzir a formação de micronúcleos em células hepáticas, apresentando, portanto um perfil similar ao observado em PCSR10.002. Assim como a atorvastatina, PCSR09.001 apresentou elevado potencial pró-apoptótico para a linhagem de hepatócitos. Já PCSR08.002, apresentou aumento na apoptose de CHO-K1. A indução de apoptose não é necessariamente um evento negativo, já que é pouco lesiva e responsável pela eliminação de células danificadas. Porém, as respostas de apoptose induzidas por esse composto foram muito inferiores àquelas induzidas pela atorvastatina (cerca de 4 vezes menor que a atorvastatina). PCSR08.002 foi aquele se mostrou menos tóxico e essa amostra foi a que teve menor risco relativo, em uma análise global das respostas de citotoxicidade e não demonstrou ter potencial genotóxico para as linhagens utilizadas nesse estudo. Conclui-se, portanto, que a análise da atividade toxicológica utilizando modelos experimentais in vitro dessas estatinas constitui um importante passo para o estabelecimento de novos candidatos à fármacos com maior segurança. / Statin drugs are competitive inhibitors of the enzyme 3-hydroxy-methyl-glutaryl coenzyme A (HMGCoA) reductase, widely used for the control of hypercholesterolemia and overall, in particular for the reduction of serum LDLc (Low Density Lipoprotein cholesterol). In addition to the primary effect, these drugs have many secondary effects, called pleiotropic effects, involving anti-inflammatory, antitumor, and antiparasitic activities. For the development of innovations in the field of medicinal chemistry is essential to evaluate the risk of adverse health effects, or in other words, the therapeutic safety of the new product under the proposed conditions of use. Accordingly, the aim of this study was to investigate the genotoxicity of four analogues of lipid biosynthesis inhibitors, from the class of statins in experimental models in vitro, previously tested against the W2 clone of Plasmodium falciparum to obtain the IC50 of these molecules against the pathogen. Four new molecules (PCSR02.001, PCSR09.001, PCSR08.002 and PCSR10.002) were developed. For the assessment of toxicity, bacterial mutagenicity test (Ames test) were performed, the cell viability assay using WST-1 reagent and micronuclei induction assay, both using an ovarian lineage (CHO-K1) and an hepatic lineage (HepG2). Taking into account the fact that none of the samples have induced mutagenic effects in strains of S. enterica serovar Typhimurium , and PCSR10.002 have shown cytotoxicity then we suggest that this compound is the most toxic. Comparatively, PCSR10.002 was more cytotoxic and genotoxic for the CHO-K1 cell line, than for HepG2 line. PCSR02.001 showed high genotoxic potential for ovarian cells, but was not able to induce the formation of micronuclei in liver cells, thus showing a similar profile to that observed in PCSR10.002. Just like atorvastatin, PCSR09.001 showed high pro-apoptotic potential for hepatocyte lineage. Have PCSR08.002, showed an increase in apoptosis of CHO-K1. The induction of apoptosis is not necessarily an adverse event, since little is harmful and responsible for the elimination of damaged cells. However, the apoptotic responses induced by this compound were much lower than those induced by atorvastatin (about 4 times less than atorvastatin). PCSR08.002 was that was less toxic and this sample had a lower relative risk in a global analysis of the responses and cytotoxicity demonstrated no genotoxic potential for strains used in this study. Therefore it is concluded that the analysis of toxicological activity using in vitro experimental models of these statins is an important step towards the establishment of more safely new candidate-drugs.
|
89 |
Význam diety v ovlivnění rizikových faktorů KVO u pacientů léčených statiny / Importance of diet in influencing the risk factors of CVD in patients treated with statinsBártová, Kateřina January 2018 (has links)
Diet and other regimens are part of the treatment of dyslipidemia, where the objective is trough modification lipid and lipoprotein metabolism, to influence the cardiovascular risk and to reduce the risk of atherothrombotic compliations. The aim of this work was to investigate the importance of different diets in influencing the risk factors of KVO in patients treated with statins, i.e. to assess the dietary habits of these patients by means of a questionnaire and to monitor the changes, from before to after, of the selected anthropometric and laboratoty parameters. The study included 41 patients of an average age of age of 50 years ± 11. The duration of statin therapy: 88 % of them over half year, 12 % of them less than six months. 73 % of them do not smoke, 27 % were smokers. The dietary habits questionnaire was completed by the patient prior to education and subsequently evaluated. The monitored parameters - weight, waist circumference, blood pressure, total cholesterol, HDL-c, non- HDL-c, LDL-c, triglycerides, glycemia, glycated hemoglobin in diabetics were evaluated before and after 2-3 months of education. Patients were predominantly familiar with the basic rules of a low fat diet but over 30% patients consume food inappropriately for the diet and over 30 % of patients did not consume foods...
|
90 |
Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo / Hypolipemiant effects on CYP3A4 and CYP3A5 mRNA expression in vitro and in vivoMaria Alice Vieira Willrich 07 October 2011 (has links)
Introdução: As CYP3A4 e CYP3A5 são enzimas do citocromo P450 responsáveis pela biotransformação de esteróides endógenos e vários fármacos, entre eles as estatinas. Polimorfismos nos genes CYP3A4 e CYP3A5 (CYP3A4*1B, CYP3A5*3C e CYP3A5*1D) foram associados com diferenças na resposta hipolipemiante de indivíduos tratados com atorvastatina e sinvastatina. Neste estudo foram avaliados os efeitos de hipolipemiantes sobre a expressão e a atividade de CYP3A4 e CYP3A5, em linhagens celulares HepG2 e Caco-2 e em CMSP de indivíduos hipercolesterolêmicos, e sua relação com variantes de CYP3A4 e CYP3A5. Métodos: Foram analisados 99 indivíduos normolipidêmicos (NL) e 139 hipercolesterolêmicos (HC). Os HC foram tratados com atorvastatina (10 mg/dia/4 semanas). A genotipagem das variantes CYP3A4*1B, CYP3A5*3C e CYP3A5*1D foi feita por PCR-RFLP ou sequenciamento. A análise da expressão de RNAm de CYP3A4 e CYP3A5 foi avaliada por PCR em tempo real quantitativo (PCRq). As proteínas totais de HepG2 foram avaliadas por Western Blotting. A atividade de CYP3A4 e CYP3A5 in vivo foi avaliada pela relação entre cortisol e seu metabólito, 6β-hidróxicortisol, na urina (razão 6βOH-cortisol/cortisol), por CLAE. Resultados: O perfil de expressão basal de RNAm de CYP3A4 e CYP3A5 é diferente entre HepG2 e Caco-2. Caco-2 expressa 31 vezes mais CYP3A4 e 122 vezes mais CYP3A5 que HepG2. Em células HepG2 tratadas por 12 h, a atorvastatina 20 µM aumentou a expressão de CYP3A4 em 10 vezes, em relação ao controle (p=0,006). Após 24 h de tratamento, atorvastatina (1-20 µM) aumentou a expressão de CYP3A4 em 5 a 8 vezes, nas HepG2 (p< 0,001). Para CYP3A5, a exposição por 12 h à atorvastatina 20 µM aumentou a expressão em 4 vezes em relação ao controle ( p<0,001). A exposição à sinvastatina 1,0 µM por 24 h aumentou a expressão de CYP3A4, em 2 vezes (p<0,01), em HepG2. Também se observou que, nesse tempo de tratamento, a sinvastatina (0,1 µM a 10 µM) aumentou a expressão de CYP3A5 em 2 a 4 vezes (p<0,05). A linhagem HepG2 apresenta alelos funcionais (CYP3A4*1A e CYP3A5*1A) em homozigose. A linhagem Caco-2 apresenta os alelos não funcionais CYP3A5*3C e CYP3A5*1D, em heterozigose. Também foi avaliada a expressão das proteínas CYP3A4 e CYP3A5 por Western Blotting, em células HepG2, após atorvastatina (0,1 a 20 µM) e sinvastatina (0,01 a 10 µM) por 12 e 24 h. O perfil de expressão das proteínas não diferiu com os tratamentos. Nas células mononucleares do sangue periférico (CMSP), a expressão de RNAm basal de CYP3A4 é cerca de 2,5 a 9,6 vezes maior que a expressão de CYP3A5 (p< 0,05). Observou-se correlação da expressão de CYP3A4 e CYP3A5 nessas células, antes (r2 = 0,22; p< 0,0001) e após o tratamento (r2 = 0,58; p<0,0001) com atorvastatina. A expressão basal de RNAm de CYP3A4 e CYP3A5 é maior nos indivíduos (NL) que nos indivíduos (HC) (p<0,05). A atorvastatina não influenciou a expressão de CYP3A4 e CYP3A5 em CMSP (p> 0,05). Os indivíduos NL apresentam atividade de CYP3A4 e CYP3A5 basal maior que os indivíduos HC- (p<0,0001). O tratamento com atorvastatina não alterou a atividade de CYP3A4 e CYP3A5 nos HC (p>0,05). As variantes gênicas estudadas (CYP3A4*1B, CYP3A5*3C e CYP3A5*1D) como grupos haplotípicos não afetaram a resposta ao tratamento, a expressão de RNAm ou a atividade de CYP3A4 e CYP3A5, embora o haplótipo AGT tenha expressão basal de RNAm de CYP3A5 menor que os portadores de haplótipos GAT e GAC (p<0,005). Conclusão: Os resultados deste trabalho nos permitem concluir que a atorvastatina e a sinvastatina, mas não a ezetimiba, influenciam a expressão de CYP3A4 e CYP3A5 in vitro, em linhagem derivada de hepatócitos (HepG2), e que este efeito não foi reproduzido em linhagem derivada de enterócitos (Caco-2). A expressão de CYP3A4 e CYP3A5 tem grande variabilidade interindividual, independente do grupo haplotípico de cada indivíduo, e que não é influenciada pela atorvastatina. / Background: CYP3A4 and CYP3A5 are enzymes from the cytochrome P450 resposible for the biotransformation of endogenous steroids and several drugs, e.g. statins. Polymorphisms in CYP3A4 and CYP3A5 (CYP3A4*1B, CYP3A5*3C and CYP3A5*1D) have been associated with variation of lipid-lowering response in individuals treated with atorvastatin and simvastatin. In this study we evaluated the effect of hypolipemiants on expression and activity of CYP3A4 and CYP3A5, in HepG2 and Caco-2 cell lines as well as peripheral blood mononuclear cells (PBMC) in hypercholesterolemic individuals, and their relationship with CYP3A4 and CYP3A5 variants. Methods: We analyzed 99 normolipidemic individuals (NL) and 139 hypercholesterolemic (HC). HC subjects were treated with atorvastatin (HC, 10 mg/day/4 weeks). Analysis of CYP3A4*1B, CYP3A5*3C e CYP3A5*1D variants was performed with PCR-RFLP or sequencing assays and mRNA expression of CYP3A4 and CYP3A5 with Quantitative Real-time PCR (qRT-PCR) was performed . Total protein content was extracted from HepG2 for Western Blotting experiments. Activity of CYP3A4 and CYP3A5 in vivo was evaluated by 6βOH-cortisol and cortisol ratio in urine samples, by HPLC-UV method. Results: Baseline mRNA expression is different for HepG2 and Caco-2. Caco-2 expresses 31 times more CYP3A4 and 122 times more CYP3A5 than HepG2. In HepG2 cells treated for 12h, atorvastatin 20 µM increased CYP3A4 expression in 10 times, when compared to the control (p=0.006). After 24h treatment, atorvastatin (1-20 µM) increased CYP3A4 mRNA expression in 5 to 8 times, in HepG2 (p< 0.001). To CYP3A5, exposure for 12h to atorvastatin 20 µM increased expression in 4 times when compared to the control (p<0.001). Exposure to simvastatin 1.0 µM for 24 h increased CYP3A4 expression in 2 times, (p<0.01), in HepG2. With the 24h treatment,simvastatin (0.1 µM - 10 µM) CYP3A5 showed increased mRNA expression in 2 to 4 times (p<0.05). HepG2 cell line carries homozygous functional alleles (CYP3A4*1A e CYP3A5*1A). Caco-2 carries heterozygous CYP3A5*3C and CYP3A5*1D. We evaluated the protein expression of CYP3A4 and CYP3A5 with Western Blotting in HepG2 cells, after atorvastatin (0.1 - 20 µM) and simvastatin (0.01 - 10 µM) for 12 and 24 h. The proteins profile did not change with statins treatment. In PBMC, baseline mRNA expression of CYP3A4 is approximately 2.6 to 9.5 times higher than CYP3A5 (p< 0.05). There was a correlation in expression between CYP3A4 and CYP3A5, before (r2 = 0.22; p< 0.0001) and after treatment (r2 = 0.58; p<0.0001) with atorvastatin. Baseline mRNA expression of CYP3A4 and CYP3A5 is higher in (NL) than in (HC) (p<0.05). Atorvastatin treatment did not increase CYP3A4 and CYP3A5 mRNA in PBMC (p>0.05). CYP3A4/5 activity was higher in NL subjects than in HC (p<0.0001). Atorvastatin treatment did not affect CYP3A4/5 activity in HC (p>0.05). The studied variants CYP3A4*1B, CYP3A5*3C e CYP3A5*1D analyzed as a haplotype block did not affect response to treatment, mRNA expression or activity of CYP3A4 and CYP3A5. However, AGT haplotype showed lower CYP3A5 mRNA expression levels when compared to GAC and GAT haplotypes at baseline (p<0.05). Conclusion: The results of this study allow us to conclude that atorvastatin and simvastatin, but not ezetimibe, influence the expression of CYP3A4 and CYP3A5 mRNA in vitro in HepG2 cell line, but this effect was not reproduced in Caco-2 cell line or PBMC. CYP3A4 and CYP3A5 present great interindividual variability, despite the individual´s haplotype and is not influenced by atorvastatin.
|
Page generated in 0.0856 seconds